Notice of Proposed Sale · 144
Cypherpunk Technologies Inc.
CYPHNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- CYPHERPUNK TECHNOLOGIES INC.
- Issuer CIK
- 0001509745
- SEC file number
- 001-37990
- Phone
- 617-714-0360
- Person for whose account securities are to be sold
- Dietz Thomas John
- Relationships to issuer
- Director
- Street
- 47 THORNDIKE STREET
- Street (continued)
- SUITE B1-1
- City
- CAMBRIDGE
- State / country code
- MA
- Postal code
- 02141
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 20,000 | 32,300.00 | 107,764,382 | 08/26/2026 | NASDAQ | Charles Schwab Corporation |
Broker / market maker — proposed row 1, entry 1
- Name
- Charles Schwab Corporation
- Street
- 3000 Schwab Way
- City
- Westlake
- State / country code
- TX
- Postal code
- 76262
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 11/11/2025 | Restricted Stock Unit | Issuer | 83,000 | N | 11/11/2025 | Equity Compensation |
| Common | 12/23/2025 | Restricted Stock Unit | Issuer | 104,500 | N | 12/23/2025 | Equity Compensation |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/26/2026
- Signed
- Thomas Dietz
Company context
Cypherpunk Technologies is a privacy technology company. The Company's mission is to advance technologies that guarantee privacy for humans on the internet. Cypherpunk pursues this mission through three primary strategies: mining Zcash through Cypherpunk Mining; accumulating Zcash through open market purchases; and investing in, acquiring, and building technologies that push the frontier of privacy forward. Additionally, through its subsidiary Leap Therapeutics, the Company is developing novel therapies for patients with cancer by continuing the development of sirexatamab and FL-501. For more information about the Company, visit our websites at http://www.cypherpunk.com and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov.